EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Open Access · CC BY-NC-ND 4.0

Efficacy and Safety of Remdesivir in People With Impaired Kidney Function Hospitalized for COVID-19 Pneumonia: A Randomized Clinical Trial

Meghan E Sise, Jose Ramon Santos, Jason D Goldman, Katherine R Tuttle, J Pedro Teixeira, Allan F Seibert, Yiannis Koullias, Joe Llewellyn, Sean Regan, Yang Zhao, Hailin Huang, Robert H Hyland und 13 weitere

Clinical Infectious Diseases · 2024

DOI: 10.1093/cid/ciae333 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Infectious Diseases, 2024. Verfasst von Meghan E Sise und 24 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Massachusetts General Hospital, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Alanine, Adenosine Monophosphate, COVID-19 Drug Treatment, Antiviral Agents. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Gilead Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Few antiviral therapies have been studied in patients with coronavirus disease 2019 (COVID-19) and kidney impairment. Herein, the efficacy, safety, and pharmacokinetics of remdesivir, its metabolites, and sulfobutylether-β-cyclodextrin excipient were evaluated in hospitalized patients with COVID-19 and severe kidney impairment.

Methods

In REDPINE, a phase 3, randomized, double-blind, placebo-controlled study, participants aged ≥12 years hospitalized for COVID-19 pneumonia with acute kidney injury, chronic kidney disease, or kidney failure were randomized 2:1 to receive intravenous remdesivir (200 mg on day 1; 100 mg daily up to day 5) or placebo (enrollment from March 2021 to March 2022). The primary efficacy end point was the composite of the all-cause mortality rate or invasive mechanical ventilation rate through day 29. Safety was evaluated through day 60.

Results

Although enrollment concluded early, 243 participants were enrolled and treated (remdesivir, n = 163; placebo, n = 80). At baseline, 90 participants (37.0%) had acute kidney injury (remdesivir, n = 60; placebo, n = 30), 64 (26.3%) had chronic kidney disease (remdesivir, n = 44; placebo, n = 20), and 89 (36.6%) had kidney failure (remdesivir, n = 59; placebo, n = 30); and 31 (12.8%) were vaccinated against COVID-19. Composite all-cause mortality or invasive mechanical ventilation rates through day 29 were 29.4% and 32.5% in the remdesivir and placebo group, respectively (P = .61). Treatment-emergent adverse events were reported in 80.4% for remdesivir versus 77.5% for placebo, and serious adverse events in 50.3% versus 50.0%, respectively. Pharmacokinetic plasma exposure to remdesivir was not affected by kidney function.

Conclusions

Although the study was underpowered, no significant difference in efficacy was observed between treatment groups. REDPINE demonstrated that remdesivir is safe in patients with COVID-19 and severe kidney impairment. Clinical Trials Registration EudraCT 2020-005416-22; Clinical Trials.gov NCT04745351.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AlanineAdenosine MonophosphateCOVID-19 Drug TreatmentAntiviral AgentsSARS-CoV-2COVID-19HospitalizationHumansMaleFemaleMiddle AgedDouble-Blind MethodAgedAcute Kidney InjuryAdultTreatment OutcomeRespiration, ArtificialAged, 80 and over

Stichwörter der Autor:innen

COVID-19SARS-CoV-2kidney impairmentremdesivir

Substanzen

remdesivirAlanineAdenosine MonophosphateAntiviral Agents

Autor:innen und Institutionen

  • Division of Nephrology, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Fight Infections Foundation, Service of Infectious Diseases, Hospital Universitari Germans Trias i Pujol, Badalona, Spain.
  • Swedish Center for Research and Innovation, Providence Swedish Medical Center, Seattle, Washington, USA.
  • Division of Allergy and Infectious Diseases, University of Washington, Seattle, Washington, USA.
  • Providence Medical Research Center, Providence Inland Northwest Health, Spokane, Washington, USA.
  • Divisions of Nephrology and Pulmonary, Critical Care, and Sleep Medicine, University of New Mexico Hospital, Albuquerque, New Mexico, USA.

Förderung

  • Gilead Sciences

Zitieren

APA

Sise, M. E., Santos, J. R., Goldman, J. D., Tuttle, K. R., Teixeira, J. P., Seibert, A. F., Koullias, Y., Llewellyn, J., Regan, S., Zhao, Y., Huang, H., Hyland, R. H., Osinusi, A., Winter, H., Humeniuk, R., Hulter, H. N., Gottlieb, R. L., Fusco, D. N., Birne, R., …, & REDPINE Investigators (2024). Efficacy and Safety of Remdesivir in People With Impaired Kidney Function Hospitalized for COVID-19 Pneumonia: A Randomized Clinical Trial. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciae333

Vancouver

Sise ME, Santos JR, Goldman JD, Tuttle KR, Teixeira JP, Seibert AF, et al. Efficacy and Safety of Remdesivir in People With Impaired Kidney Function Hospitalized for COVID-19 Pneumonia: A Randomized Clinical Trial. Clinical Infectious Diseases. 2024. doi:10.1093/cid/ciae333

BibTeX
@article{Sise2024,
  author = {Sise, Meghan E and Santos, Jose Ramon and Goldman, Jason D and Tuttle, Katherine R and Teixeira, J Pedro and Seibert, Allan F and Koullias, Yiannis and Llewellyn, Joe and Regan, Sean and Zhao, Yang and Huang, Hailin and Hyland, Robert H and Osinusi, Anu and Winter, Helen and Humeniuk, Rita and Hulter, Henry N and Gottlieb, Robert L and Fusco, Dahlene N and Birne, Rita and Stancampiano, Fernando F and Libertin, Claudia R and Small, Catherine B and Plate, Markus and McPhail, Mark J and REDPINE Investigators, REDPINE Investigators},
  title = {Efficacy and Safety of Remdesivir in People With Impaired Kidney Function Hospitalized for COVID-19 Pneumonia: A Randomized Clinical Trial},
  journal = {Clinical Infectious Diseases},
  year = {2024},
  doi = {10.1093/cid/ciae333}
}
Kostenlos starten →